Fig. 2

Severity Rutherford’s classification decreased in auto-BM-MNC and allo-WJ-MSC—treated diabetic patients with CTLI. Rutherford’s classification decreased in the auto-BM-MNC and allo-WJ-MSC groups starting from the first month (Rutherford < 3), which persisted until 12 months after cell-based therapy, unlike the placebo group, whose participants increased their classification to a more severe stage of the disease (Rutherford 6). Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (p < 0.05); placebo group versus allo-WJ-MSC group (*) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group three months post-treatment (@) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group three months post-treatment (ϕ) (p < 0.05); placebo group pre-treatment versus placebo group six months post-treatment (&) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group six months post-treatment (φ) (p < 0.05); placebo group pre-treatment versus placebo group twelve months post-treatment ($) (p < 0.05) and allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group twelve months post-treatment (Ψ) (p < 0.05). Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cells